Regeneron and intellia announce expanded research collaboration to develop crispr-based therapies for the treatment of neurological and muscular diseases

Collaboration combines intellia's leading genome editing platform, including its proprietary nme2cas9 technology, with regeneron's proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases
REGN Ratings Summary
REGN Quant Ranking